EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 359 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours February 10, 2026 Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line... July 17, 2023 Pioneer in Autism Diagnosis And Treatment Dies At 97 September 21, 2021 Women and girls in science: We won’t stop pushing for progress February 11, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ Job Loss During Cancer: How to Cope and Continue Treatment
